A Potential and Novel Therapeutic Approach to Ischemic Heart Diseases: Notch3.

Xin Yi,Gaoke Feng,Xuejun Jiang
DOI: https://doi.org/10.1016/j.ijcard.2017.04.093
IF: 4.039
2017-01-01
International Journal of Cardiology
Abstract:Recently, the original paper entitled “Notch3 deficiency impairs coronary microvascular maturation and reduces cardiac recovery after myocardial ischemia” reported by Yong-Kang Tao and colleagues attracted our interest [ [1] Tao Y.K. Zeng H. Zhang G.Q. Chen S.T. Xie X.J. He X. et al. Notch3 deficiency impairs coronary microvascular maturation and reduces cardiac recovery after myocardial ischemia. Int. J. Cardiol. 2017; 236: 413-422 Abstract Full Text Full Text PDF PubMed Scopus (16) Google Scholar ]. Their results revealed that Notch3 deficiency reduced cardiac pericyte coverage, impaired coronary blood flow reserve, and ultimately increased ischemic area post myocardial infarction (MI) via inhibiting CXCR4/SDF-1α and VEGF/Ang-1 signaling pathways [ [1] Tao Y.K. Zeng H. Zhang G.Q. Chen S.T. Xie X.J. He X. et al. Notch3 deficiency impairs coronary microvascular maturation and reduces cardiac recovery after myocardial ischemia. Int. J. Cardiol. 2017; 236: 413-422 Abstract Full Text Full Text PDF PubMed Scopus (16) Google Scholar ]. Therefore, Notch3 might be a novel therapeutic approach to MI centered at increasing pericyte/progenitor cell recruitment and vascular maturation. Cardiac fibrosis which is characterized by excessive deposition of scar tissue significantly reduces cardiac function after MI [ [2] Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ. Res. 2010; 106: 1675-1680 Crossref PubMed Scopus (549) Google Scholar ]. Thus, anti-fibrotic therapy is promising in curbing fibrosis and enhancing cardiac function after MI [ [3] Sassoli C. Chellini F. Pini A. Tani A. Nistri S. Nosi D. et al. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-beta/Smad3 signaling. PLoS One. 2013; 8e63896 Crossref PubMed Scopus (111) Google Scholar ]. Zhang et al. demonstrated that Notch3 inhibited cardiac fibroblast-myofibroblast transition in MI mice and in cultured CFs with TGF-β1 stimulus by inhibiting TGF-β1/Smad3 signaling pathway to reduce cardiac fibrosis [ [4] Zhang M. Pan X. Zou Q. Xia Y. Chen J. Hao Q. et al. Notch3 ameliorates cardiac fibrosis after myocardial infarction by inhibiting the TGF-beta1/Smad3 pathway. Cardiovasc. Toxicol. 2016; 16: 316-324 Crossref PubMed Scopus (35) Google Scholar ]. Zhang et al. also reported that Oncostatin M (OSM) significantly alleviated cardiac ischemia/reperfusion (I/R) injury via Notch3/Akt signaling pathway. OSM receptor Oβ knockout also promoted cardiomyocyte apoptosis, impaired mitochondrial function, exacerbated I/R injury, and inhibited Notch3 production. However, Notch3 overexpression alleviated, while Notch3 siRNA treatment aggravated cardiac I/R injury in mice [ [5] Zhang M. Wang C. Hu J. Lin J. Zhao Z. Shen M. et al. Notch3/Akt signaling contributes to OSM-induced protection against cardiac ischemia/reperfusion injury. Apoptosis. 2015; 20: 1150-1163 Crossref PubMed Scopus (26) Google Scholar ]. Collectively, these findings supported that Notch3 is a potential therapeutic target for ischemic heart diseases by promoting pericyte/progenitor cell recruitment and vascular maturation, inhibiting cardiac fibrosis, improving mitochondrial function, and alleviating cardiac dysfunction. Notch3 deficiency impairs coronary microvascular maturation and reduces cardiac recovery after myocardial ischemiaInternational Journal of CardiologyVol. 236PreviewVascular maturation plays an important role in wound repair post-myocardial infarction (MI). The Notch3 is critical for pericyte recruitment and vascular maturation during embryonic development. Full-Text PDF
What problem does this paper attempt to address?